Windtree Therapeutics, Inc. (WINT)
NASDAQ: WINT · Real-Time Price · USD
0.510
+0.043 (9.13%)
Nov 20, 2024, 4:00 PM EST - Market closed
Windtree Therapeutics Employees
Windtree Therapeutics had 20 employees as of December 31, 2022. The number of employees decreased by 13 or -39.39% compared to the previous year.
Employees
20
Change (1Y)
-13
Growth (1Y)
-39.39%
Revenue / Employee
n/a
Profits / Employee
-$569,200
Market Cap
4.46M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Predictive Oncology | 35 |
Genprex | 26 |
Hepion Pharmaceuticals | 22 |
Sonoma Pharmaceuticals | 10 |
Pasithea Therapeutics | 8 |
Chromocell Therapeutics | 8 |
Artelo Biosciences | 6 |
Silo Pharma | 3 |
WINT News
- 4 weeks ago - Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World - GlobeNewsWire
- 4 weeks ago - Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan - GlobeNewsWire
- 7 weeks ago - Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock - GlobeNewsWire
- 7 weeks ago - Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET - GlobeNewsWire
- 2 months ago - Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock - GlobeNewsWire
- 3 months ago - Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates - GlobeNewsWire
- 3 months ago - Windtree Announces New Additions and Changes to Its Board of Directors - GlobeNewsWire
- 4 months ago - Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data - GlobeNewsWire